These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 12907319)

  • 1. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow.
    Ryan BM; Russel MG; Langholz E; Stockbrugger RW
    Am J Gastroenterol; 2003 Aug; 98(8):1682-7. PubMed ID: 12907319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
    Bernstein CN; Blanchard JF; Metge C; Yogendran M
    Am J Gastroenterol; 2003 Dec; 98(12):2784-8. PubMed ID: 14687833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.
    Stange EF
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():64-7. PubMed ID: 16961748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates.
    Munkholm P; Loftus EV; Reinacher-Schick A; Kornbluth A; Mittmann U; Esendal B
    Digestion; 2006; 73(1):11-9. PubMed ID: 16410688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
    Chan EP; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of colorectal cancer in inflammatory bowel disease.
    Subramanian V; Logan RF
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):593-606. PubMed ID: 22122774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
    Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
    Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Aminosalicylates in the treatment of idiopathic inflammatory bowel disease].
    Lukás K
    Vnitr Lek; 1996 Feb; 42(2):117-9. PubMed ID: 8686186
    [No Abstract]   [Full Text] [Related]  

  • 10. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
    van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
    Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inflammatory bowel disease and colorectal cancer].
    Hagymási K; Tulassay Z
    Orv Hetil; 2006 Oct; 147(41):1977-82. PubMed ID: 17120688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
    Bernstein CN; Nugent Z; Blanchard JF
    Am J Gastroenterol; 2011 Apr; 106(4):731-6. PubMed ID: 21407180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for 'best evidence'?
    Giannini EG; Kane SV; Testa R; Savarino V
    Dig Liver Dis; 2005 Oct; 37(10):723-31. PubMed ID: 16023905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Aminosalicylic acid inhibits colitis-associated but not sporadic colorectal neoplasia in a novel conditional Apc mouse model.
    Koelink PJ; Robanus-Maandag EC; Devilee P; Hommes DW; Lamers CB; Verspaget HW
    Carcinogenesis; 2009 Jul; 30(7):1217-24. PubMed ID: 19420017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminosalicylates.
    Campregher C; Gasche C
    Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):535-46. PubMed ID: 22122769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment of patients who have colorectal cancer and inflammatory bowel disease.
    Goessling W; Mayer RJ
    Gastroenterol Clin North Am; 2006 Sep; 35(3):713-27. PubMed ID: 16952747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IBD-related carcinoma and lymphoma.
    Claessen MM; Siersema PD; Vleggaar FP
    Best Pract Res Clin Gastroenterol; 2011 Apr; 25 Suppl 1():S27-38. PubMed ID: 21640928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
    Lopez A; Collet-Fenetrier B; Belle A; Peyrin-Biroulet L
    J Dig Dis; 2016 Jun; 17(6):383-91. PubMed ID: 27129893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesalamine protects against colorectal cancer in inflammatory bowel disease.
    Tang J; Sharif O; Pai C; Silverman AL
    Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.